Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Epacadostat in Recurrent Ovarian Clear Cell Carcinoma
NCT03602586Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of epacadostat in ovarian clear cell carcinoma (OCCC), sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response at 7 months. Started Dec 2018; status: completed.
02
Drugs
epacadostat
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT03602586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602586.